Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Blood test can predict preterm preeclampsia with 80% accuracy February 12, 2025 Study highlights widespread adverse events in surgical care November 13, 2024 Tiny titin mutation linked to developmental heart defects and adult atrial fibrillation July 25, 2024
Tiny titin mutation linked to developmental heart defects and adult atrial fibrillation July 25, 2024